en.Wedoany.com Reported - Whoosh Wellness has officially launched in Newport Beach, California, offering a premium, physician-guided telehealth platform that provides approved remote health solutions for health-conscious adults. The platform introduces two core differentiators in the telehealth market: all programs are available in oral dosage forms, and all GLP-1 regimens are designed around physician-prescribed microdosing protocols to reduce side effects and achieve long-term results. Serving performance-driven professionals, fitness-focused adults, and longevity-seeking consumers, Whoosh allows members to complete an online health assessment, remotely connect with licensed physicians, and receive personalized health plans delivered directly to their door.

The platform offers oral dosage forms for all its products, including oral options for its semaglutide, tirzepatide, NAD+, sermorelin, and glutathione regimens. This approach aims to address common barriers to starting and adhering to health programs, such as needle aversion or lifestyle disruption. According to co-founder Carter Jenkins, many people who could truly benefit from these programs never start because the experience feels too clinical or complicated, and Whoosh was built to eliminate that friction. When all programs are available in both traditional and oral forms, the barrier to entry is lowered, compliance improves, and the overall experience feels more like a natural part of daily life rather than a medical intervention. A Phase 3 clinical trial evaluating once-daily oral semaglutide showed statistically significant improvements in glycemic control across all tested doses over 26 weeks, with the 14 mg dose group achieving meaningful weight loss. Early human trial data from Lexaria Bioscience also indicates that its oral tirzepatide capsules achieved blood concentration levels comparable to injectable forms, with fewer reported side effects.

For GLP-1 regimens, Whoosh adopts a different approach from the standard stepwise titration. Each Whoosh GLP-1 program is built around prescribed microdosing, where physicians find the lowest effective dose for each individual rather than defaulting to the maximum dose. Jenkins notes that the goal is sustainable metabolic optimization, not short-term suppression. Clinical evidence shows that high doses of semaglutide and tirzepatide are associated with more pronounced gastrointestinal side effects, including nausea, vomiting, and fatigue. Microdosing allows patients to achieve meaningful appetite control and metabolic benefits at lower doses while reducing side effects and improving long-term adherence. Physicians within the platform focus on determining the dose that optimizes appetite and metabolic function, rather than the highest dose a patient can tolerate.

All Whoosh programs use only approved compounds and are dispensed under physician supervision through licensed compounding pharmacies. The platform's current program library includes semaglutide, tirzepatide, sermorelin, NAD+, and glutathione, all available in oral dosage forms. Each member receives ongoing physician-guided care, with doctors monitoring progress and adjusting regimens based on response. Dr. Todd Strumwasser, MD, serves as the in-house medical advisor for Whoosh Wellness. He is a board-certified anesthesiologist with over 40 years of medical leadership experience, a graduate of the Keck School of Medicine of USC, and completed his residency at the University of Washington Affiliated Hospitals, where he served as chief resident. His career includes executive leadership roles at CommonSpirit Health and Dignity Health, focusing on patient care quality, clinical operations, and medical innovation.

The Whoosh platform is now live at www.whooshwellness.com.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com